Cost-effectiveness of FRAX®-based intervention thresholds for management of osteoporosis in Singaporean women

[en] Summary: Cost-effectiveness analysis of FRAX® intervention thresholds (ITs) in Singaporean women > 50 years of age showed that generic alendronate was cost-effective at age-dependent major osteoporotic fracture (MOF) IT from the ages of 65 years for both full and real-world adherence whilst hip fracture (HF) ITs were cost-effective from the ages of 60 and 65 years. Alendronate was cost-effective irrespective of age only at fixed MOF IT of 14% and HF IT of 3.5%. Introduction: FRAX®-based intervention thresholds (ITs) were recently identified for osteoporosis management in Singapore. This study aimed to assess the cost-effectiveness of ITs in Singaporean women over the age of 50 years. Methods: A validated Markov microsimulation model was used to estimate the lifetime healthcare costs (SGD2019) per quality-adjusted life-years (QALY) of generic alendronate compared with no treatment. Cost-effectiveness of age-dependent FRAX® major osteoporotic fracture (MOF) and hip fracture (HF) ITs was explored. In addition, ITs that would lead to cost-effectiveness were computed. Fracture incidence and cost data were obtained from the Ministry of Health and a previously published Singaporean study. A cost-effectiveness threshold of SGD 62,500/QALY gained was used, based conservatively on 0.7 times the Singapore GDP per capita. Results: Generic alendronate was shown to be cost-effective at MOF ITs from the ages of 65 years, while HF ITs were cost-effective from the ages of 60 and 65 years, assuming full and real-world adherence, respectively. A 14% MOF and a 3.5% HF ITs were required for alendronate to be cost-effective above 50 years. Conclusion: This study suggests that the treatment of Singaporean women with alendronate is cost-effective at age-dependant FRAX® intervention thresholds at 65 years and older. Furthermore, identifying women at any age above 50 years with a 10-year risk of MOF or HF of 14% or 3.5% would lead to efficient use of resources. Cost-effective access to therapy for patients at high fracture probability based on FRAX® could contribute to reduce the growing burden of osteoporotic fractures in Singapore. © 2020, The Author(s).

Disciplines :

Public health, health care sciences & services

Author, co-author :

Chandran, M.; Osteoporosis and Bone Metabolism Unit, Department of Endocrinology, Singapore General Hospital, Singapore, Singapore

Ganesan, G.; Ministry of Health, Singapore, Singapore

Tan, K. B.; Ministry of Health, Singapore, Singapore, School of Public Health, National University of Singapore, Singapore, Singapore

Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé

Hiligsmann, M.; Department of Health Services Research, CAPHRI Care and Public Health Research Institute, Maastricht University, Maastricht, Netherlands

Language :

English

Title :

Cost-effectiveness of FRAX®-based intervention thresholds for management of osteoporosis in Singaporean women

Publication date :

January 2021

Journal title :

Osteoporosis International

ISSN :

0937-941X

eISSN :

1433-2965

Publisher :

Springer

Volume :

Issue :

Pages :

133-144

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 21 October 2020

Statistics

Number of views

52 (4 by ULiège)

Number of downloads

41 (2 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Odén A, McCloskey EV, Kanis JA, Harvey NC, Johansson H (2015) Burden of high fracture probability worldwide: secular increases 2010-2040. Osteoporos Int 26(9):2243–2248 DOI: 10.1007/s00198-015-3154-6
https://population.un.org/wpp/Publications/Files/WPP2017_KeyFindings.pdf. Last accessed April 26 2020
Cheung CL, Ang SB, Chadha M, Chow ESL, Chung YS, Hew FL, Jaisamrarn U, Ng H, Takeuchi Y, Wu CH, Xia W, Yu J, Fujiwara S (2018) An updated hip fracture projection in Asia: the Asian Federation of Osteoporosis Societies study. Osteoporosis and sarcopenia 4(1):16–21 DOI: 10.1016/j.afos.2018.03.003
Mohd-Tahir NA, Li SC (2017) Economic burden of osteoporosis-related hip fracture in Asia: a systematic review. Osteoporos Int 28(7):2035–2044 DOI: 10.1007/s00198-017-3985-4
https://www.singstat.gov.sg/modules/infographics/economy. Last Accessed December 1 2019
Chandran M, Lau TC, Gagnon-Arpin I, Dobrescu A, Li W, Leung MYM, Patil N, Zhao Z (2019) The health and economic burden of osteoporotic fractures in Singapore and the potential impact of increasing treatment rates through more pharmacological options. Arch Osteoporos 14(1):114 DOI: 10.1007/s11657-019-0664-4
https://www.aihw.gov.au/reports/chronic-musculoskeletal-conditions/snapshot-of-osteoporosis-australia-2011, Last accessed April 26 2020
Bliuc D, Nguyen ND, Milch VE, Nguyen TV, Eisman JA, Center JR et al (2009) Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 301(5):513–521 DOI: 10.1001/jama.2009.50
Johnell O, Kanis JA, Odén A, Sernbo I, Redlund-Johnell I, Petterson C et al (2004) Mortality after osteoporotic fractures. Osteoporos Int 15(1):38 DOI: 10.1007/s00198-003-1490-4
Malhotra R, Bautista MAC, Müller AM, Aw S, Koh GCH, Theng YL, Hoskins SJ, Wong CH, Miao C, Lim WS, Malhotra C, Chan A (2019) The aging of a young nation: population aging in Singapore. Gerontologist May 59(3):401–410
Kanis JA, Johnell O, Oden A, Jonsson B, De Laet C, Dawson A et al (2000) Risk of hip fracture according to the World Health Organization criteria for osteopenia and osteoporosis. Bone 27(5):585–590 DOI: 10.1016/S8756-3282(00)00381-1
Siris ES, Miller PD, Barrett-Connor E, Faulkner KG, Wehren LE, Abbott TA, Berger ML, Santora AC, Sherwood LM (2001) Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA 286(22):2815–2822 DOI: 10.1001/jama.286.22.2815
Chandran M (2017) Fracture risk assessment in clinical practice: why do it? What to do it with? J Clin Densitom 20(3):274–279 DOI: 10.1016/j.jocd.2017.06.010
Kanis JA, Harvey NC, Cooper C, Johansson H, Oden A, McCloskey EV, Advisory Board of the National Osteoporosis Guideline Group (2016) A systematic review of intervention thresholds based on FRAX: a report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation. Archives of Osteoporos 11(1):25 DOI: 10.1007/s11657-016-0278-z
Tosteson ANA, Melton LJ, Dawson-Hughes B, Baim S, Favus MJ, Khosla S et al (2008) Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int 19(4):437–447 DOI: 10.1007/s00198-007-0550-6
Kanis JA, McCloskey EV, Johansson H, Strom O, Borgstrom F, Oden A et al (2008) Case finding for the management of osteoporosis with FRAX--assessment and intervention thresholds for the UK. Osteoporos Int 19(10):1395–1408 DOI: 10.1007/s00198-008-0712-1
Lippuner K, Johansson H, Borgström F, Kanis JA, Rizzoli R (2012) Cost-effective intervention thresholds against osteoporotic fractures based on FRAX® in Switzerland. Osteoporos Int 23(11):2579–2589 DOI: 10.1007/s00198-011-1869-6
Chandran M, McCloskey EV, Thu WPP, Logan S, Hao Y, Tay D et al (2018) FRAX® based intervention thresholds for management of osteoporosis in Singaporean women. Arch Osteoporos 13(1):130 DOI: 10.1007/s11657-018-0542-5
Compston J, Cooper A, Cooper C, Francis R, Kanis JA, Marsh D, McCloskey E, Reid DM, Selby P, Wilkins M, National Osteoporosis Guideline Group (NOGG) (2009) Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas 62(2):105–108 DOI: 10.1016/j.maturitas.2008.11.022
MacLean C, Newberry S, Maglione M, McMahon M, Ranganath V, Suttorp M, Mojica W, Timmer M, Alexander A, McNamara M, Desai SB, Zhou A, Chen S, Carter J, Tringale C, Valentine D, Johnsen B, Grossman J (2008) Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 148(3):197–213 DOI: 10.7326/0003-4819-148-3-200802050-00198
Hiligsmann M, Ethgen O, Bruyère O, Richy F, Gathon HJ, Reginster JY et al (2009) Development and validation of a Markov microsimulation model for the economic evaluation of treatments in osteoporosis. Value Health 12(5):687–696 DOI: 10.1111/j.1524-4733.2008.00497.x
Hiligsmann M, Williams SA, Fitzpatrick LA, Silverman SS, Weiss R, Reginster JY et al (2019) Cost-effectiveness of sequential treatment with abaloparatide vs. teriparatide for United States women at increased risk of fracture. Semin Arthritis Rheum 49(2):184–196 DOI: 10.1016/j.semarthrit.2019.01.006
Pearce F, Lin L, TeoEl NK, Khoo D (2019) Health technology assessment and its use in drug policies: Singapore. Value in Health regional issues 18:176–183 DOI: 10.1016/j.vhri.2018.03.007
Hiligsmann M, Reginster JY, Tosteson ANA, Bukata SV, Saag KG, Gold DT, Halbout P, Jiwa F, Lewiecki EM, Pinto D, Adachi JD, al-Daghri N, Bruyère O, Chandran M, Cooper C, Harvey NC, Einhorn TA, Kanis JA, Kendler DL, Messina OD, Rizzoli R, Si L, Silverman S (2019) Recommendations for the conduct of economic evaluations in osteoporosis: outcomes of an experts’ consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the US branch of the International Osteoporosis Foundation. Osteoporos Int 30(1):45–57 DOI: 10.1007/s00198-018-4744-x
Yong EL, Ganesan G, Kramer MS, Logan S, Lau TC, Cauley JA, Tan KB (2019) Hip fractures in Singapore: ethnic differences and temporal trends in the new millennium. Osteoporos Int 30(4):879–886 DOI: 10.1007/s00198-019-04839-5
Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA 3rd, Berger M (2000) Patients with prior fractures have an increased risk of future fractures; a summary of the literature and statistical synthesis. J Bone Miner Res 15:721–739 DOI: 10.1359/jbmr.2000.15.4.721
Kanis JA, Johnell O, De Laet C et al (2004) A meta-analysis of previous fracture and subsequent fracture risk. Bone35:375–382
Johnell O, Kanis JA, Oden A et al (2004) Fracture risk following an osteoporotic fracture. Osteoporos Int 15:175–179 DOI: 10.1007/s00198-003-1514-0
DOS mortality rates. https://singstat.gov.sg/publicfacing/createDataTable.action?refid=13249 Last Accessed 1 Dec 2019
Parker MJ, Anand JK (1991) What is the true mortality of hip fracture? Public Health 105:443–446 DOI: 10.1016/S0033-3506(05)80614-6
Svedbom A, Borgstöm F, Hernlund E, Ström O, Alekna V, Bianchi ML, Clark P, Curiel MD, Dimai HP, Jürisson M, Kallikorm R, Lember M, Lesnyak O, McCloskey E, Sanders KM, Silverman S, Solodovnikov A, Tamulaitiene M, Thomas T, Toroptsova N, Uusküla A, Tosteson ANA, Jönsson B, Kanis JA (2018) Quality of life for up to 18 months after low-energy hip, vertebral, and distal forearm fractures-results from the ICUROS. Osteoporos Int 29(3):557–566 DOI: 10.1007/s00198-017-4317-4
Hiligsmann M, Ethgen O, Richy F, Reginster JY (2008) Utility values associated with osteoporotic fracture: a systematic review of the literature. Calcif Tissue Int 82(4):288–292 DOI: 10.1007/s00223-008-9117-6
Hanmer J, Lawrence WF, Anderson JP, Kaplan RM, Fryback DG (2006) Report of nationally representative values for the noninstitutionalized US adult population for 7 health-related quality-of-life scores. Med Decis Mak 26(4):391–400 DOI: 10.1177/0272989X06290497
Wade SW, Satram-Hoang S, Nadkar A, Macarios D, Tosteson ANA (2011) Impact of medication adherence on health care utilization and productivity: self-reported data from a cohort of postmenopausal women on osteoporosis therapy. Clin Ther 33(12):2006–2015 DOI: 10.1016/j.clinthera.2011.10.021
Cheen MH, Kong MC, Zhang RF, Tee FM, Chandran M (2012) Adherence to osteoporosis medications amongst Singaporean patients. Osteoporos Int Mar 23(3):1053–1060 DOI: 10.1007/s00198-011-1635-9
Hiligsmann M, Boonen A, Rabenda V, Reginster JY (2012) The importance of integrating medication adherence into pharmacoeconomic analyses: the example of osteoporosis. Expert review of pharmacoeconomics & outcomes research 12(2):159–166 DOI: 10.1586/erp.12.8
National Institute for Health and Clinical Excellence (NICE). Systematic reviews of clinical effectiveness prepared for the guideline “Osteoporosis assessment of fracture risk and the prevention of osteoporotic fractures in individuals at high risk https://www.nice.org.uk/guidance/ta464/chapter/3-Committee-discussion#clinical-effectiveness Last accessed December 1 2019
Hiligsmann M, Evers SM, Ben Sedrine W, Kanis JA, Ramaekers B, Reginster JY, Silverman S, Wyers CE, Boonen A (2015) A systematic review of cost-effectiveness analyses of drugs for postmenopausal osteoporosis. Pharmacoeconomics 33(3):205–224 DOI: 10.1007/s40273-014-0231-1
Ström O, Landfeldt E, Garellick G (2015) Residual effect after oral bisphosphonate treatment and healthy adherer effects--the Swedish Adherence Register Analysis (SARA). Osteoporos Int 26(1):315–325 DOI: 10.1007/s00198-014-2900-5
Hiligsmann M, McGowan B, Bennett K, Barry M, Reginster JY (2012) The clinical and economic burden of poor adherence and persistence with osteoporosis medications in Ireland. Value Health 15(5):604–612 DOI: 10.1016/j.jval.2012.02.001
Fatoye F, Smith P, Gebrye T, Yeowell G (2019) Real-world persistence and adherence with oral bisphosphonates for osteoporosis: a systematic review. BMJ Open 9(4):e027049 DOI: 10.1136/bmjopen-2018-027049
World Health Organization. CHOosing Interventions that are Cost Effective (WHO-CHOICE): cost effectiveness thresholds. http://www.who.int/choice/costs/CER_thresholds/en/ Last accessed December 1 2019
Chan DC, McCloskey EV, Chang CB, Lin KP, Lim LC, Tsai KS, Yang RS (2017) Establishing and evaluating FRAX® probability thresholds in Taiwan. J Formos Med Assoc Mar 116(3):161–168 DOI: 10.1016/j.jfma.2016.03.006
Harvey NC, McCloskey E, Kanis JA, Compston J, Cooper C (2017) Bisphosphonates in osteoporosis: NICE and easy? Lancet 390(10109):2243–2244 DOI: 10.1016/S0140-6736(17)32850-7
Kanis JA, McCloskey E, Johnson B, Cooper A, Strom O, Borgstrom F (2010) An evaluation of the NICE guidance for the prevention of osteoporotic fragility fractures in postmenopausal women. Archives of Osteoporosis 5:19–48 DOI: 10.1007/s11657-010-0045-5
https://iofbonehealth.org/data-publications/regionalaudits/asia-pacific-regionalaudit. Last accessed April 26 2020
Chandran M, Chin YA, Choo KS, Ang WC et al (2020) Comparison of the osteoporosis self-assessment tool for Asians and the fracture risk assessment tool - FRAX to identify densitometric defined osteoporosis: aA discriminatory value analysis in a multi-ethnic female population in Southeast Asia. Osteoporosis and Sarcopenia. 10.1016/j.afos.2020.04.001
Chandran M, Ang SB, Au L, et al. (2018) Appropriate care guide: osteoporosis identification and management in primary care. Singapore: Ministry of Health. http://www.ace-hta.gov.sg/our-guidance/osteoporosis-identification-and-management-in-primary-care.html. Last accessed April 26 2020
Kanis JA, Reginster JY, Kaufman JM, Ringe JD, Adachi JD, Hiligsmann M, Rizzoli R, Cooper C (2012) A reappraisal of generic bisphosphonates in osteoporosis. Osteoporos Int 23(1):213–221 DOI: 10.1007/s00198-011-1796-6
Kanis JA, Adams J, Borgstrom F, Cooper C, Johnson B, Preedy D, Selby P, Compston J (2007) The cost-effectiveness of alendronate in the management of osteoporosis. Bone 42(1):4–115 DOI: 10.1016/j.bone.2007.10.019
https://southeastasiaglobe.com/how-southeast-asian-countries-compare-growth-development/. Last accessed April 26 2020